PubRank
Search
About
Ponatinib in Advanced NSCLC w/ RET Translocations
Clinical Trial ID NCT01813734
PubWeight™ 15.48
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01813734
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Oncologist
2013
2.04
2
Refining the treatment of NSCLC according to histological and molecular subtypes.
Nat Rev Clin Oncol
2015
1.24
3
Molecular pathways and therapeutic targets in lung cancer.
Oncotarget
2014
1.16
4
Targeted therapies in development for non-small cell lung cancer.
J Carcinog
2013
1.12
5
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Transl Lung Cancer Res
2015
1.07
6
Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
Semin Oncol
2013
1.03
7
Resistant mutations in CML and Ph(+)ALL - role of ponatinib.
Biologics
2014
0.99
8
Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Front Oncol
2014
0.92
9
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
BMC Cancer
2015
0.83
10
Targeted therapies and immunotherapy in non-small-cell lung cancer.
Ecancermedicalscience
2016
0.82
11
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.
Mol Aspects Med
2015
0.81
12
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Front Oncol
2016
0.79
13
The minority report: targeting the rare oncogenes in NSCLC.
Curr Treat Options Oncol
2014
0.78
14
Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.
J Thorac Oncol
2015
0.78
15
Genomics driven-oncology: challenges and perspectives.
BMC Cancer
2015
0.76
16
RET-targeting molecular stratified non-small-cell lung cancers.
Transl Lung Cancer Res
2013
0.76
Next 100